Admetsys wins FDA breakthrough nod for automated glucose control tech

The PrecisionOne system provides automated glucose control and continuous blood diagnostics. [Image from the Admetsys website]Admetsys announced today that it received FDA breakthrough device designation for its automated glucose control system.

The system — also a continuous blood diagnostics system — aims to fill a key gap in the standard of care. Boston-based Admetsys designed it to automatically measure multiple blood analytes, including glucose, in real-time. It requires no patient blood loss.

From the measurement, it creates an adaptive, computational model of each patient’s metabolism. The system evolves with the patient condition, delivering precisely optimized insulin and dextrose treatments through multiple infusion channels.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0